| Bartlett's Hearing Aid Center | |
|
2201 Pillsbury Rd Ste 194, Chico, CA 95926-1373 | |
| (530) 343-2350 | |
| (530) 343-2505 |
| Full Name | Bartlett's Hearing Aid Center |
|---|---|
| Type | Facility |
| Speciality | Hearing Instrument Specialist |
| Location | 2201 Pillsbury Rd Ste 194, Chico, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013239037 | NPI | - | NPPES |
| ZZZ76038Z | Medicaid | CA |
| Mailing Address | Practice Location Address |
|---|---|
| Bartlett's Hearing Aid Center 2201 Pillsbury Rd Ste 194, Chico, CA 95926-1373 Ph: () - | Bartlett's Hearing Aid Center 2201 Pillsbury Rd Ste 194, Chico, CA 95926-1373 Ph: (530) 343-2350 |
News Archive
Blood flow to the heart often is interrupted during a heart attack or cardiac surgery. But when blood flow resumes, the heart may still falter. That's because collateral damage can occur as blood re-enters the heart, potentially slowing recovery and causing future cardiac troubles.
EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO will be commercially available in the United States in the third quarter of 2012.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that effective January 3, 2011, it will begin trading on the NASDAQ Global Select Market. The NASDAQ Global Select Market is the highest NASDAQ listing tier based on financial and liquidity criteria. Prior to the effectiveness of this change in the New Year, shares of Spectrum Pharmaceuticals will continue to be traded on the NASDAQ Global Market.
New research hints that the common belief that kids who go to daycare have lower rates of asthma and allergy later in life might be nothing more than wishful thinking. While young children in daycare definitely do get more illnesses and experience more respiratory symptoms as a result, any perceived protection these exposures afford against asthma and allergy seem to disappear by the time the child hits the age of eight.
› Verified 4 days ago